BRISTOL-MYERS SQUIBB COMPANY Segment Reporting Information, Depreciation Expense (Deprecated 2011-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Segment Reporting Information, Depreciation Expense (Deprecated 2011-01-31) of $380.00 million for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SegmentReportingInformationDepreciationExpense · last filed 2011-02-18
- BRISTOL-MYERS SQUIBB COMPANY segment reporting information, depreciation expense (deprecated 2011-01-31) for fiscal 2010 was $380.00M, a 9.83% increase from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY segment reporting information, depreciation expense (deprecated 2011-01-31) for fiscal 2009 was $346.00M, a 4.16% decline from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY segment reporting information, depreciation expense (deprecated 2011-01-31) for fiscal 2008 was $361.00M.
| Period end | Segment Reporting Information, Depreciation Expense (Deprecated 2011-01-31) 12 month |
|---|---|
| 2010-12-31 | $380.00M 10-K · filed 2011-02-18 |
| 2009-12-31 | $346.00M 10-K · filed 2011-02-18 |
| 2008-12-31 | $361.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |